利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

78 条记录 (耗时 0.062 秒)

    Apparatus and method for circuit operation definition
    1.
    发明授权
    Apparatus and method for circuit operation definition 有权
    电路操作定义的装置和方法

    公开(公告)号：US07530034B2

    公开(公告)日：2009-05-05

    申请号：US11363787

    申请日：2006-02-27

    申请人： Martin Betz ,  Lokesh Johri ,  Rajesh Jain ,  Theodore R. Lundquist ,  Tamal Basu ,  Saurabh Gupta ,  Jagadish Narayana Gade

    发明人： Martin Betz ,  Lokesh Johri ,  Rajesh Jain ,  Theodore R. Lundquist ,  Tamal Basu ,  Saurabh Gupta ,  Jagadish Narayana Gade

    IPC分类号： G06F17/50

    CPC分类号： G06F17/5068

    摘要： A method and apparatus for defining a circuit operation, such as a charged particle beam operation to perform a circuit edit and define a probe point. Circuit operation definition is performed in a front-end environment with access to integrated circuit computer aided design tools providing logic level and layout level information concerning the integrated circuit. The front-end environment incorporates circuit operation optimization methods to identify optimal locations for a circuit operation. A back-end environment, such as a charged particle tool computing platform, is adapted to receive one or more files, which may include a truncated layout file with circuit operation location information, for use in further defining a circuit operation and/or performing the circuit operation.

    摘要翻译： 一种用于定义电路操作的方法和装置，例如带电粒子束操作以执行电路编辑并定义探测点。 电路操作定义在前端环境中执行，可访问集成电路计算机辅助设计工具，提供有关集成电路的逻辑电平和布局级信息。 前端环境包含电路操作优化方法，以确定电路操作的最佳位置。 诸如带电粒子工具计算平台的后端环境适于接收一个或多个文件，其可以包括具有电路操作位置信息的截断的布局文件，以用于进一步定义电路操作和/或执行 电路操作。

    Extended release compositions comprising mycophenolate sodium and processes thereof
    3.
    发明授权
    Extended release compositions comprising mycophenolate sodium and processes thereof 有权

    公开(公告)号：US09642808B2

    公开(公告)日：2017-05-09

    申请号：US12672180

    申请日：2008-08-11

    申请人： Rajesh Jain ,  Sukhjeet Singh ,  Sampath Kumar Devarajan

    发明人： Rajesh Jain ,  Sukhjeet Singh ,  Sampath Kumar Devarajan

    IPC分类号： A61K31/343 ,  A61K9/20 ,  A61K9/28 ,  A61K31/365

    CPC分类号： A61K9/2077 ,  A61K9/2013 ,  A61K9/2846 ,  A61K31/365

    摘要： Extended release pharmaceutical compositions comprising mycophenolate sodium as the active agent, wherein the said composition exhibits a characteristic release profile when subjected to in-vitro dissolution study, and wherein said mycophenolate sodium is released in a sustained manner in-vivo for a prolonged duration in such quantities that substantially alleviates or at least reduces the chances of causing any associated gastrointestinal side effect(s) without compromising the bioavailability of the said active agent are provided. The present invention also provides process of preparing dosage form compositions and prophylactic and/or therapeutic methods of using such dosage form. The compositions of the present invention are useful for the management such as prophylaxis, amelioration and/or treatment of immunosuppressant indicated disease(s)/disorder(s) especially for the treatment or prevention of organ, tissue or cellular allograft or xenograft rejection, e.g. after transplant, or the management of immune-mediated diseases (autoimmune diseases).

    Combination vaccine with acellular pertussis
    5.
    发明授权
    Combination vaccine with acellular pertussis 有权
    具有无细胞百日咳组合疫苗

    公开(公告)号：US08551451B2

    公开(公告)日：2013-10-08

    申请号：US13125708

    申请日：2009-10-23

    申请人： Rajesh Jain ,  Sukhjeet Singh ,  Lavit Jambu

    发明人： Rajesh Jain ,  Sukhjeet Singh ,  Lavit Jambu

    IPC分类号： A61K49/00 ,  A61K39/00 ,  A61K39/02

    CPC分类号： A61K39/05 ,  A61K39/0018 ,  A61K39/08 ,  A61K39/099 ,  A61K39/102 ,  A61K39/12 ,  A61K39/13 ,  A61K39/292 ,  A61K2039/5252 ,  A61K2039/55505 ,  A61K2039/70 ,  C12N2730/10134 ,  C12N2770/32634 ,  Y02A50/466

    摘要： The present invention relates to a combination vaccine comprising a mixture of antigens for protection against diseases such as diphtheria, tetanus, acellular pertussis, and infections caused by Haemophilus influenzae and polio viruses. The present invention also relates to inclusion of antigens for protection against infections caused Hepatitis virus and other pathogens, such that administration of the vaccine can simultaneously immunize a subject against more than one pathogen. The invention in particular relates to a fully liquid stable combination vaccine comprising the antigens as indicated above and the methods for manufacturing the same.

    摘要翻译： 本发明涉及包含抗原混合物的组合疫苗，用于防止诸如白喉，破伤风，无细胞百日咳和由流感嗜血杆菌和脊髓灰质炎病毒引起的感染。 本发明还涉及包含用于防止引起的肝炎病毒和其他病原体的感染的抗原，使得疫苗的施用可以同时针对多于一种的病原体免疫受试者。 本发明特别涉及包含上述抗原的完全液体稳定的组合疫苗及其制备方法。

    NOVEL BICYCLIC COMPOUNDS
    6.
    发明申请
    NOVEL BICYCLIC COMPOUNDS 有权
    新型双环化合物

    公开(公告)号：US20130253029A1

    公开(公告)日：2013-09-26

    申请号：US13876757

    申请日：2011-09-27

    申请人： Rajesh Jain ,  Sanjay Trehan ,  Jagattaran Das ,  Nishan Singh ,  Sudhir Kumar Sharma

    发明人： Rajesh Jain ,  Sanjay Trehan ,  Jagattaran Das ,  Nishan Singh ,  Sudhir Kumar Sharma

    IPC分类号： C07D209/52 ,  A61K45/06 ,  A61K31/403

    CPC分类号： C07D209/52 ,  A61K31/403 ,  A61K45/06

    摘要： The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention further provides pharmaceutical compositions comprising compounds of Formula I and methods of treating or preventing one or more disorders of the central and/or peripheral nervous system, preferably by modulating neurological and/or psychiatric targets (GPCR and/or non-GPCR).

    摘要翻译： 本发明涉及式I的新化合物，其药学上可接受的衍生物，互变异构形式，异构体，多晶型物，前药，代谢物，盐或溶剂化物。 本发明还涉及合成式I的新化合物，其药学上可接受的衍生物，互变异构形式，异构体，多晶型物，前药，代谢物，盐或溶剂合物的方法。 本发明还提供包含式I化合物的药物组合物和治疗或预防中枢和/或周围神经系统的一种或多种病症的方法，优选通过调节神经和/或精神病学靶标（GPCR和/或非GPCR） 。

    EXTENDED RELEASE COMPOSITIONS COMPRISING MYCOPHENOLATE SODIUM AND PROCESSES THEREOF
    7.
    发明申请
    EXTENDED RELEASE COMPOSITIONS COMPRISING MYCOPHENOLATE SODIUM AND PROCESSES THEREOF 有权
    包含MYCOPHENOLATE SODIUM的扩展性释放组合物及其过程

    公开(公告)号：US20110223249A1

    公开(公告)日：2011-09-15

    申请号：US12672180

    申请日：2008-08-11

    申请人： Rajesh Jain ,  Sukhjeet Singh ,  Sampath Kumar Devarajan

    发明人： Rajesh Jain ,  Sukhjeet Singh ,  Sampath Kumar Devarajan

    IPC分类号： A61K31/343 ,  A61K9/00 ,  A61K9/24 ,  A61K9/28 ,  A61P35/00 ,  A61P11/00 ,  A61P25/00 ,  A61P9/00 ,  A61P29/00 ,  A61P31/00

    CPC分类号： A61K9/2077 ,  A61K9/2013 ,  A61K9/2846 ,  A61K31/365

    摘要： Extended release pharmaceutical compositions comprising mycophenolate sodium as the active agent, wherein the said composition exhibits a characteristic release profile when subjected to in-vitro dissolution study, and wherein said mycophenolate sodium is released in a sustained manner in-vivo for a prolonged duration in such quantities that substantially alleviates or at least reduces the chances of causing any associated gastrointestinal side effect(s) without compromising the bioavailability of the said active agent are provided. The present invention also provides process of preparing dosage form compositions and prophylactic and/or therapeutic methods of using such dosage form. The compositions of the present invention are useful for the management such as prophylaxis, amelioration and/or treatment of immunosuppressant indicated disease(s)/disorder(s) especially for the treatment or prevention of organ, tissue or cellular allograft or xenograft rejection, e.g. after transplant, or the management of immune-mediated diseases (autoimmune diseases).

    摘要翻译： 包含霉酚酸钠作为活性剂的延长释放药物组合物，其中当进行体外溶出研究时，所述组合物表现出特征性释放曲线，并且其中所述霉酚酸钠以持续的方式在体内以这种方式长时间释放 提供了大大减轻或至少降低引起任何相关胃肠道副作用而不损害所述活性剂的生物利用度的机会的量。 本发明还提供了使用这种剂型的剂型组合物和预防和/或治疗方法的制备方法。 本发明的组合物可用于治疗，例如预防，改善和/或治疗指示的疾病/病症，特别是用于治疗或预防器官，组织或细胞同种异体移植物或异种移植物排斥反应的免疫抑制剂，例如， 移植后，或免疫介导的疾病（自身免疫性疾病）的管理。

    Novel Pharmaceutical Modified Release Dosage Form Cyclooxygenase Enzyme Inhibitor
    9.
    发明申请
    Novel Pharmaceutical Modified Release Dosage Form Cyclooxygenase Enzyme Inhibitor 审中-公开
    新型药物改性释放剂型环氧合酶抑制剂

    公开(公告)号：US20100204333A1

    公开(公告)日：2010-08-12

    申请号：US11988860

    申请日：2006-07-19

    申请人： Rajesh Jain ,  Kour Chand Jindal ,  Sukhjeet Singh ,  Munish Talwar

    发明人： Rajesh Jain ,  Kour Chand Jindal ,  Sukhjeet Singh ,  Munish Talwar

    IPC分类号： A61K31/18 ,  A61P25/00 ,  A61P25/06

    CPC分类号： A61K9/2018 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2059 ,  A61K9/209 ,  A61K9/4808 ,  A61K9/4858 ,  A61K9/4866 ,  A61K9/5084 ,  A61K31/18 ,  A61K31/192 ,  A61K31/415

    摘要： Pharmaceutical modified release dosage form comprising at least one cyclooxygenase enzyme inhibitor or its pharmaceutically acceptable salts, esters, prodrugs, solvates, hydrates, or derivatives thereof as active agent, with a pharmaceutically acceptable carrier for controlling the release of the cyclooxygenase enzyme inhibitor is provided. The dosage form preferably provides a release of not more than about 60% of the cyclooxygenase enzyme inhibitor in 1 hour and not less than about 75% of the cyclooxygenase enzyme inhibitor after 12 hours when tested in accordance with the dissolution method (I) described herein employing Distilled water with 2.0% Sodium lauryl sulphate as the dissolution medium or in accordance with the dissolution method (II) described herein employing pH 7.0 Phosphate buffer with 2.0% Sodium lauryl sulphate as the dissolution medium or in accordance with the dissolution method (III) described herein employing 0.001 N Hydrochloric acid with 1.0% Sodium lauryl sulphate as dissolution medium. Further, the pharmaceutical composition of the present invention when tested in a group of healthy humans preferably achieves a mean peak plasma concentration (Cmax) after at least about 1 hour of administration of the dosage form. The present invention also provides process of preparing such dosage form compositions and prophylactic and/or therapeutic methods of using such dosage form.

    摘要翻译： 提供了包含至少一种环加氧酶酶抑制剂或其药学上可接受的盐，酯，前药，溶剂化物或其衍生物作为活性剂的药物改性释放剂型，以及用于控制环加氧酶抑制剂释放的药学上可接受的载体。 根据本文所述的溶解方法（I）测试时，剂型优选在12小时后提供不超过约60％的环氧合酶抑制剂的释放量，并且不少于约75％的环氧合酶抑制剂。 使用2.0％十二烷基硫酸钠作为溶解介质的蒸馏水或根据本文所述的溶解方法（II），使用pH 7.0的磷酸盐缓冲液，含有2.0％十二烷基硫酸钠作为溶解介质，或根据溶解方法（III） 本文使用0.001N盐酸与1.0％十二烷基硫酸钠作为溶解介质。 此外，当在一组健康人中测试时，本发明的药物组合物优选在施用剂型至少约1小时后达到平均峰值血浆浓度（C max）。 本发明还提供了制备这种剂型组合物的方法和使用这种剂型的预防和/或治疗方法。

    NOVEL LOW DOSE PHARMACEUTICAL COMPOSITIONS COMPRISING NIMESULIDE, PREPARATION AND USE THEREOF
    10.
    发明申请
    NOVEL LOW DOSE PHARMACEUTICAL COMPOSITIONS COMPRISING NIMESULIDE, PREPARATION AND USE THEREOF 审中-公开
    包含NIMESULIDE的新型低剂量药物组合物，其制备和使用

    公开(公告)号：US20090258947A1

    公开(公告)日：2009-10-15

    申请号：US12298054

    申请日：2007-04-23

    申请人： Rajesh Jain ,  Kour Chand Jindal

    发明人： Rajesh Jain ,  Kour Chand Jindal

    IPC分类号： A61K31/16 ,  A61P25/00

    CPC分类号： A61K31/18 ,  A61K9/0019 ,  A61K9/0095 ,  A61K9/2018 ,  A61K9/2846 ,  A61K9/2866 ,  A61K9/485 ,  A61K9/4858

    摘要： Low dose pharmaceutical dosage form comprising nimesulide or its pharmaceutically acceptable salts, esters, solvates or hydrates thereof, along with one or more pharmaceutically acceptable excipient(s) are provided. The present invention also provides process of preparing such dosage forms and therapeutic methods of using such dosage forms. The low dose compositions 10 are designed to exhibit such bioavailability, which is effective in the treatment of NSAID indicated disorders particularly, which require long-term treatment regimens such as arthritis. Such compositions reduce the cost of therapy in diseases, which require long-term therapies, are easy to manufacture, and also result in the reduction of dose related side effects associated with nimesulide therapy.

    摘要翻译： 提供了包含尼美舒利或其药学上可接受的盐，酯，溶剂化物或其水合物以及一种或多种药学上可接受的赋形剂的低剂量药物剂型。 本发明还提供了制备这种剂型的方法和使用这种剂型的治疗方法。 低剂量组合物10被设计为表现出这样的生物利用度，其在治疗特别是需要长期治疗方案例如关节炎的NSAID指征的病症中是有效的。 这样的组合物降低了需要长期疗法，易于制备的疾病的治疗成本，并且还导致与尼美舒利治疗相关的剂量相关的副作用的减少。